| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cell surface A33 antigen; Gpa33;;GPA33 |
| WB Predicted band size | Calculated MW: 36 kDa ; Observed MW: 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human GPA33 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于GPA33抗体的3篇参考文献的简要总结(注：内容基于模拟文献信息，可能与实际研究存在差异)：
---
1. **文献名称**：*GPA33 as a Novel Target for Antibody-Based Immunotherapy in Colorectal Cancer*
**作者**：Smith A, et al.
**摘要**：研究证实GPA33在结直肠癌细胞表面高表达，而在正常组织中表达受限。通过开发靶向GPA33的单克隆抗体，在体外和小鼠模型中显著抑制肿瘤生长，表明其作为免疫治疗靶点的潜力。
2. **文献名称**：*Structural Characterization of GPA33 Epitopes for Therapeutic Antibody Design*
**作者**：Zhang L, et al.
**摘要**：利用X射线晶体学解析了GPA33胞外结构域的三维构象，并鉴定了其与特异性抗体结合的关键表位。该研究为优化抗体药物亲和力和特异性提供了结构基础。
3. **文献名称**：*GPA33/CD3 Bispecific Antibody Enhances T-cell Mediated Tumor Clearance*
**作者**：Jones R, et al.
**摘要**：报道了一种靶向GPA33和CD3的双特异性抗体，可有效引导T细胞识别并杀伤GPA33阳性肿瘤细胞。临床前实验显示该抗体显著提升抗肿瘤活性，且未观察到明显毒性。
---
如需获取真实文献，建议通过PubMed或Google Scholar以关键词“GPA33 antibody”或“GPA33 immunotherapy”检索近期研究。
The GPA33 antibody targets Glycoprotein A33 (GPA33), a transmembrane glycoprotein belonging to the immunoglobulin superfamily. First identified in the 1990s, GPA33 is highly expressed in normal gastrointestinal epithelial cells and overexpressed in several cancers, particularly colorectal carcinoma (CRC), making it a tumor-associated antigen of interest in oncology research. Structurally, it contains extracellular immunoglobulin-like domains involved in cell-cell adhesion and signaling, though its precise physiological role remains under investigation.
GPA33's selective overexpression in CRC has driven its exploration as a diagnostic and therapeutic target. Antibodies against GPA33. such as the murine monoclonal A33 antibody, have been engineered for clinical applications. Early-phase trials demonstrated that radiolabeled anti-GPA33 antibodies could selectively localize CRC tumors, enabling radioimmunotherapy or imaging. More recently, bispecific antibodies and antibody-drug conjugates (ADCs) targeting GPA33 have been developed to enhance tumor-specific cytotoxicity while sparing healthy tissues.
Despite promising preclinical data, clinical translation faces challenges, including heterogeneous antigen expression in tumors and immune-related adverse effects. Current research focuses on optimizing antibody formats, combination therapies with checkpoint inhibitors, and patient stratification based on GPA33 expression levels. As a cell surface antigen with restricted normal tissue distribution, GPA33 remains a compelling target for precision oncology, particularly in gastrointestinal malignancies.
×
